StockNews.AI
ALGS
StockNews.AI
4 hrs

Aligos Therapeutics Announces Eight Abstracts Accepted at The Liver Meeting® 2025

1. ALGS to present Phase 1 data on ALG-000184 at Liver Meeting 2025. 2. Oral presentation on ALG-000184's suppression of HBV DNA planned for November 9. 3. Multiple poster presentations will cover ALG's advancements in HBV therapies. 4. Clinical stage status highlights ALGS's ongoing drug development efforts. 5. Potential for ALG-000184 to become first-in-class in treating chronic HBV.

8m saved
Insight
Article

FAQ

Why Bullish?

Positive data from clinical trials often correlate with stock price increases, similar to past biotech companies after presenting effective treatments.

How important is it?

The data presentation can strongly influence investor perception and confidence in ALGS.

Why Short Term?

The upcoming presentation can lead to immediate stock reactions, as seen with similar biotech announcements.

Related Companies

GILDNOVNBMRN
Oral presentation will include the full 96-week and post-treatment follow up data from the Phase 1 monotherapy study of ALG-000184 October 07, 2025 08:30 ET  | Source: Aligos Therapeutics SOUTH SAN FRANCISCO, Calif., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced eight presentations, including one oral presentation, at The Liver Meeting® 2025, being held November 7 – 11, 2025 in Washington, D.C. The abstracts released today can be found on the AASLD website at https://www.aasld.org/the-liver-meeting. Details on the abstracts are as follows: ALG-000184: Potential first-/best-in-class small molecule CAM-E for chronic hepatitis B virus (HBV) infection Publication #: 0198Type: Oral PresentationTitle: Oral Once -Daily 300 mg ALG-000184, a Novel Capsid Assembly Modulator Demonstrates potent suppression of HBV DNA in Treatment-Naive or Currently-not-treated Subjects with Chronic HBVPresenter: Professor Man-Fung Yuen, MBBS, MD, PhD, DSc, Chair and Chief of the Division of Gastroenterology and Hepatology, University of Hong KongDate/Time: November 9, 2025 at 5:00pm – 6:30pm ETSession: Next-generation HBV Therapeutics: Emerging Therapies and Search for Functional Cure Publication #: 1208Type: Poster PresentationTitle: Sustained Reduction of HBV Antigen Levels During the 8-Week Follow-up Period in Treatment Naïve (TN) or Currently-Not-Treated (CNT) HBeAg-Positive Subjects with Chronic Hepatitis B Virus Infection After 96-Week 300 mg ALG-000184Presenter: Professor Man-Fung Yuen, MBBS, MD, PhD, DSc, Chair and Chief of the Division of Gastroenterology and Hepatology, University of Hong KongDate/Time: November 7, 2025 at 8:00am – 5:00pm ETSession: Hepatitis B (“1118-1367”) Publication #: 1251Type: Poster PresentationTitle: Capsid Assembly Modulator ALG-001075 Prevents cccDNA Formation and HBV DNA Integration In VitroPresenter: Jordi VerheyenDate/Time: November 7, 2025 at 8:00am – 5:00pm ETSession: Hepatitis B (“1118-1367”)  Publication #: 1338Type: Poster PresentationTitle: Capsid Assembly Modulator ALG-001075 Binds and Directly Targets HBeAgPresenter: Jordi VerheyenDate/Time: November 7, 2025 at 8:00am – 5:00pm ETSession: Hepatitis B (“1118-1367”) Preclinical Publication #: 1248Type: Poster PresentationTitle: Differentiation of HBV capsid assembly modulators based on stabilization of core protein oligomerization and residence timePresenter: Cheng Liu, PhDDate/Time: November 7, 2025 at 8:00am – 5:00pm ETSession: Hepatitis B (“1118-1367”) Publication #: 1330Type: Poster PresentationTitle: CAM-E and CAM-A Compounds Differentially Affect Phosphorylated and Non-Phosphorylated Hepatitis B Core Protein In VitroPresenter: Rene Geissler, PhD, Abbott Diagnostics DivisionDate/Time: November 7, 2025 at 8:00am – 5:00pm ETSession: Hepatitis B (“1118-1367”) Publication #: 1155Type: Poster PresentationTitle: Lead Optimization and Selection of a Potential Best-in-Class HBV ASOPresenter: Jin Hong, PhDDate/Time: November 7, 2025 at 8:00am – 5:00pm ETSession: Hepatitis B (“1118-1367”) Publication #: 1103Type: Poster PresentationTitle: Two Pre-clinical Short Interfering RNA Molecules Targeting Human HSD17beta13 for the Treatment of Metabolic Dysfunction-Associated SteatohepatitisPresenter: Jieun Song, PhDDate/Time: November 7, 2025 at 8:00am – 5:00pm ETSession: MASLD/MASH - Experimental: Basic ("1001-1117") About Aligos Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical stage biotechnology company founded with the mission to improve patient outcomes by developing best-in-class therapies for the treatment of liver and viral diseases. Aligos applies its science driven approach and deep R&D expertise to advance its purpose-built pipeline of therapeutics for high unmet medical needs such as chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), and coronaviruses. For more information, please visit www.aligos.com or follow us on LinkedIn or X. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered “forward-looking statements,” including without limitation, statements regarding Aligos’ financial results and performance as well as research and development activities, including regulatory status and the timing of announcements and updates relating to our regulatory filings and clinical trials. Such forward looking statements are subject to substantial risks and uncertainties that could cause our development programs, future results, performance, or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties inherent in the drug development process, including Aligos’ clinical-stage of development, the process of designing and conducting clinical trials, the regulatory approval processes, and other matters that could affect the sufficiency of Aligos’ capital resources to fund operations. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Aligos in general, see Aligos’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 6, 2025 and its future periodic reports to be filed or submitted with the Securities and Exchange Commission. Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events. Investor ContactAligos Therapeutics, Inc.Jordyn TaraziVice President, Investor Relations & Corporate Communications+1 (650) 910-0427jtarazi@aligos.com Media ContactInizio EvokeJake RobisonVice PresidentJake.Robison@inizioevoke.com

Related News